Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 4/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9107441 | 1.00 | OPRD1 (0.44) | OPRD1OPRL1OPRM1SLC6A9CYP2D6 | |
| SCHEMBL2278150 | 1.00 | OPRD1 (0.44) | OPRD1OPRL1OPRM1SLC6A9CYP2D6 | |
| SCHEMBL9099058 | 1.00 | OPRD1 (0.44) | OPRD1OPRL1OPRM1SLC6A9CYP2D6 | |
| SCHEMBL14663792 | 1.00 | OPRD1 (0.44) | OPRD1OPRL1OPRM1SLC6A9CYP2D6 | |
| SCHEMBL14663793 | 1.00 | OPRD1 (0.44) | OPRD1OPRL1OPRM1SLC6A9CYP2D6 | |
| SCHEMBL24802139 | 1.00 | OPRD1 (0.44) | OPRD1OPRL1OPRM1SLC6A9CYP2D6 | |
| SCHEMBL5454649 | 1.00 | OPRD1 (0.44) | OPRD1OPRL1OPRM1SLC6A9CYP2D6 | |
| Hydrochloric Acid SCHEMBL9760294 | 0.98 | OPRD1 (0.43) | OPRD1OPRL1OPRM1SLC6A9CYP2D6 | |
| Hydrochloric Acid SCHEMBL9760302 | 0.98 | OPRD1 (0.43) | OPRD1OPRL1OPRM1SLC6A9CYP2D6 | |
| Hydrochloric Acid SCHEMBL9760309 | 0.98 | OPRD1 (0.43) | OPRD1OPRL1OPRM1SLC6A9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289801-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-09-18 | — | — | US | disclosed |
| EP-4359400-B1 | SALT AND CRYSTAL FORM OF AN AZETIDINYL SUBSTITUTED ISOQUINLINE ACTING AS EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR FOR THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORP (US) | 2025-07-02 | — | — | EP | disclosed |
| CN-119912478-A | Amino heteroaryl macrocyclic compounds, preparation method and application thereof | 北京鞍石生物科技股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20250129047-A1 | ISOQUINOLINE DERIVATIVES AS MUTANT EGFR MODULATORS AND USES THEREOF | NEWAVE PHARMACEUTICAL INC (US) | 2025-04-24 | — | — | US | disclosed |
| CN-119731165-A | Indazole compounds | 泰拉生物科学公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-115135642-B | Inhibitors of EGFR mutant forms | 缆图药品公司 | 2025-03-04 | — | — | CN | disclosed |
| US-12172983-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240382483-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION | 2024-11-21 | — | — | US | disclosed |
| CN-118871433-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240308981-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION | 2024-09-19 | — | — | US | disclosed |
| WO-2005077897-A1 | SUBSTITUTED AZETIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | WO | disclosed |
| US-20050187208-A1 | Substituted Azetidine compounds, their preparation and use as medicaments | LABORATORIOS DE DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | US | disclosed |
| EP-0406112-B1 | 1-Benzhydrylazetidines, their preparation and their use as intermediates for the preparation of compounds with antimicrobial activity | ESTEVE LABOR DR (ES) | 1994-12-28 | — | — | EP | disclosed |
| US-5183902-A | Muscle relaxants | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-02-02 | — | — | US | disclosed |
| US-5151418-A | Muscle relaxants | A. H. ROBINS COMPANY, INCORPORATED (US) | 1992-09-29 | — | — | US | disclosed |
| US-5073646-A | Chemical intermediates, microbiocides | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1991-12-17 | — | — | US | disclosed |
| US-5068231-A | Ureas and thioureas for relaxing muscles | A. H. ROBINS COMPANY INCORPORATED (US) | 1991-11-26 | — | — | US | disclosed |
| EP-0406112-A1 | 1-Benzhydrylazetidines, their preparation and their use as intermediates for the preparation of compounds with antimicrobial activity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1991-01-02 | — | — | EP | disclosed |
| US-4956359-A | CARBOXAMIDES OR THIOCARBOXAMIDES OF ARYL OXY OR THIO AZETIDINES | A. H. ROBINS COMPANY, INC. (US) | 1990-09-11 | — | — | US | disclosed |
| EP-0194112-A1 | 3-Aryl-oxyazetidinecarboxamides having anti-muscle tension, anti-muscle spasticity, anticonvulsant and antiepilectic activity | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129047-A1 | ISOQUINOLINE DERIVATIVES AS MUTANT EGFR MODULATORS AND USES THEREOF | EGFR, ERBB2, ERBB4 | OPRD1 833/4885OPRL1 1116/4885OPRM1 1067/4885 |
| US-12172983-B2 | EGFR inhibitors | EGFR, ERBB2, ERBB3 | OPRD1 3765/4885OPRL1 3114/4885OPRM1 3616/4885 |
| US-20240308981-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB4 | OPRD1 2945/4885OPRL1 1622/4885OPRM1 2332/4885 |
| US-20240382483-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB4 | OPRD1 2945/4885OPRL1 1622/4885OPRM1 2332/4885 |
| US-20050187208-A1 | Substituted Azetidine compounds, their preparation and use as medicaments | AZI2, NISCH, QDPR | OPRD1 340/4885OPRL1 1279/4885OPRM1 829/4885 |
| US-20250289801-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | OPRD1 3765/4885OPRL1 3114/4885OPRM1 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.